0001437749-23-006923.txt : 20230316 0001437749-23-006923.hdr.sgml : 20230316 20230316164712 ACCESSION NUMBER: 0001437749-23-006923 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230316 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 23739482 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 bioli20230316_8k.htm FORM 8-K bioli20230316_8k.htm
false 0000834365 0000834365 2023-03-16 2023-03-16
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 16, 2023
 
BIOLIFE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
  
001-36362
  
94-3076866
(State or other jurisdiction of
incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
 
3303 Monte Villa Parkway,
Bothell, WA 98021
(Address of principal executive offices) (Zip Code)
 
Registrant’s telephone number, including area code: (425) 402-1400
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
BioLife Solutions, Inc. Common Stock
BLFS
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02         Results of Operations and Financial Condition.
 
On March 16, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the fourth quarter and year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.
 
Financial information in the press release reflects unaudited results for the applicable periods. The Company’s financial statements for the fourth quarter and year ended December 31, 2022 may be subject to adjustments between the date of the press release and the completion of the audit and filing of the Company’s Annual Report on Form 10-K. Consequently, the financial information in the Company’s audited financial statements, when available, may differ from the information provided in the press release.
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit No.
  
Description
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
BioLife Solutions, Inc.
  
     
Date: March 16, 2023
By:
/s/ Troy Wichterman
  
   
Name: Troy Wichterman
Title: Chief Financial Officer
  
 
 
 EX-99.1 2 ex_489845.htm EXHIBIT 99.1 ex_489845.htm

Exhibit 99.1

 

pic1.jpg

 

BioLife Solutions Reports Preliminary and Unaudited 2022 Fourth Quarter and Full Year Financial Results

 

Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier

 

Record Q4 2022 revenue of $44.3 million increased 19% over 2021; biopreservation media revenue growth of 35%

 

Full year adjusted EBITDA of $3.6 million and Q4 2022 adjusted EBITDA of $1.7 million

 

Conference call begins at 4:30 p.m. Eastern time today

 

BOTHELL, Wash. (March 16, 2023) – BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.

 

Mike Rice, Chairman and CEO, commented, “We closed 2022 with another year of strong performance and growth, driven by solid execution across our portfolio. Our success indicators of new customer acquisition, adoption of our cell processing solutions in cell and gene therapy applications, and growth of our storage services platform all point to continued validation of our class-defining bioproduction tools and services as highly preferred in our target markets. For the full year 2022, we gained over 1,300 new customers via our direct sales team and global network of distributors. Our engineering, quality and operations teams continued to focus on supply chain and other optimization initiatives for our freezers and thaw platform and we expect to continue to drive a mix shift to high margin, recurring revenue.”

 

Troy Wichterman, Chief Financial Officer, remarked, “We achieved full year 2022 positive adjusted EBITDA of $3.6 million and ended the year with $64.1 million in cash and short-term investments. As of today, Silicon Valley Bank is operational and fully honoring existing credit facilities. We currently have no additional need for capital.”

 

Operational Highlights

 

New Customer Acquisition

 

Platform/Solution

Q4 2022

FY2022

Biopreservation Media

15

69

Sexton Cell Processing

5

33

SciSafe® Storage Services

26

99

Thaw

7

35

evo® Cold Chain

12

43

Cryogenic Freezers

13

82

ULT Freezers

139

461

TOTAL

217

822

 

 
 

 

pic1.jpg

 

 

●

New distributor indirect customers totaled at least 500 in FY2022, bringing total new customers to over 1,300 for the year.
 

●

USA Master File cross references for our cell processing solutions were 27 in Q4 and 80 in FY 2022. Total global clinical applications with our cell processing solutions embedded are now estimated to be over 600, including 12 approved therapies, with 5 additional approvals possible in 2023. Sexton cell processing solutions are now embedded in 3 approved CGT medicines and in over 60 clinical trials.
 

●

evo cold chain management shipments of cell and gene therapies totaled 2,241 in Q4 and 7,201 in FY 2022, representing over 200% annual growth over 2021.

 

 

Fourth Quarter 2022 Financial Results

 

BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP). A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

 

REVENUE

 

 

●

Total revenue for the fourth quarter of 2022 was $44.3 million, an increase of $7.0 million, or 19%, from $37.3 million for the fourth quarter of 2021. COVID-19 related revenue was approximately 5%, compared with approximately 15% in Q4 2021.

 

 

o

Cell Processing platform revenue was $20.2 million, up $5.3 million, or 36%, over the same period in 2021. Biopreservation growth was 35%.

 

 

o

Freezers and Thaw Systems platform revenue was $17.4 million, up $806,000, or 5%, over the same period in 2021. COVID-19 related revenue in 2022 was approximately 3% for this platform.

 

 

o

Storage and Storage Services platform revenue was $6.7 million, up $810,000, or 14%, over the same period in 2021. COVID-19 related revenue in 2022 was approximately 21% for this platform.

 

 

●

Total revenue for 2022 was $161.8 million, an increase of $42.6 million, or 36%, from $119.2 million for 2021. Organic revenue growth was 38%. COVID-19 related revenue was approximately 8%, compared with approximately 15% in 2021.

 

 

o

Cell Processing platform revenue was $68.5 million, up $23.5 million, or 52%, over 2021. Biopreservation media and organic cell processing growth were both 45%.

 

 

o

Freezers and Thaw Systems platform revenue was $66.8 million, up $10.1 million, or 18%, over 2021. Organic growth was 9%. COVID-19 related revenue in 2022 was approximately 4%.

 

2 of 13
 

 

pic1.jpg

 

 

o

Storage and Storage Services platform revenue was $26.5 million, up $8.9 million, or 51% over 2021; all growth was organic. COVID-19 related revenue in 2022 was approximately 39%.

 

GROSS MARGIN

 

 

●

Gross margin (GAAP) for the fourth quarter of 2022 was 30% compared with 13% for the fourth quarter of 2021. Adjusted gross margin (non-GAAP) for the fourth quarter of 2022 was 32% compared with 17% for the fourth quarter of 2021.

 

 

●

Gross margin (GAAP) for 2022 was 30% compared with 27% for 2021. Adjusted gross margin (non-GAAP) for 2022 was 33% compared with 32% for 2021.

 

 

●

The increase in quarterly gross margin and adjusted gross margin was primarily due to decreased warranty expenses compared with 2021.

 

OPERATING EXPENSE

 

 

●

Operating expense (GAAP) for the fourth quarter of 2022 was $93.5 million compared with $54.9 million for the fourth quarter of 2021. Adjusted operating expense (non-GAAP) for the fourth quarter of 2022 was $22.1 million compared with $19.2 million for the fourth quarter 2021.

 

 

●

Operating expense (GAAP) for 2022 was $307.3 million compared with $154.3 million for 2021. Adjusted operating expense (non-GAAP) for 2022 was $83.4 million compared with $59.6 million for 2021.

 

 

●

The increase in GAAP operating expense for the fourth quarter of 2022 was primarily due to a non-cash impairment charge of $40.5 million related to the acquired intangible assets of Global Cooling, Inc. (Stirling Ultracold). The increase in GAAP operating expense for 2022 was primarily due to non-cash impairment charges of $110.4 million related to the acquired intangible assets of Global Cooling, full period of ownership following the acquisition of Global Cooling on May 3, 2021, and the acquisition of Sexton Biotechnologies, Inc. on September 1, 2021, and personnel costs. Adjusted operating expenses (non-GAAP) increased due to the full period of ownership from the acquisition of Global Cooling and the acquisition of Sexton, Inc. In addition, operating expenses increased due to higher accounting costs related to becoming an Accelerated Filer, additional headcount to support our growth, and historical true-up of indirect tax expense.

 

OPERATING LOSS

 

 

●

Operating loss (GAAP) for the fourth quarter of 2022 was $49.3 million compared with $17.6 million for the fourth quarter of 2021. Adjusted operating loss (non-GAAP) for the fourth quarter of 2022 was $8.2 million compared with $13.1 million for the fourth quarter of 2021.

 

3 of 13
 

 

pic1.jpg

 

 

●

Operating loss (GAAP) for 2022 was $145.5 million compared with $35.2 million for 2021. Adjusted operating loss (non-GAAP) for 2022 was $29.3 million compared with $21.5 million for 2021.

 

NET LOSS

 

 

●

Net loss (GAAP) for the fourth quarter of 2022 was $49.2 million compared with $14.8 million for the fourth quarter of 2021. Adjusted net loss (non-GAAP) for the fourth quarter of 2022 was $8.2 million compared with $12.9 million for the fourth quarter of 2021.

 

 

●

Net loss (GAAP) for 2022 was $139.8 million compared with $8.9 million for 2021. Adjusted net loss (non-GAAP) for 2022 was $29.3 million compared with $15.4 million for 2021.

 

EARNINGS/(LOSS) PER SHARE

 

 

●

Loss per share (GAAP) for the fourth quarter of 2022 was $1.15 compared with loss per share of $0.36 for the fourth quarter of 2021.

 

 

●

Loss per share (GAAP) for 2022 was $3.29 and included non-cash intangible impairment charges of $2.60 per share. This is compared with loss per share of $0.23 for 2021.

 

ADJUSTED EBITDA

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the fourth quarter of 2022 was $1.7 million compared with negative $5.9 million for the fourth quarter of 2021.

 

 

●

Adjusted EBITDA, a non-GAAP measure, for the full year of 2022 was positive $3.6 million compared with $4.1 million for 2021.

 

CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

 

 

●

Cash, cash equivalents, and marketable securities as of December 31, 2022, were $64.1 million.

 

4 of 13
 

 

pic1.jpg

 

2023 Revenue Guidance

 

Mike Rice, Chairman and CEO, further commented, “We fully expect to participate in the forecasted growth of the CGT industry over the next several years. Sustained catalysts that we expect to drive BioLife growth due to a significant increase in the number of manufactured doses include:

 

 

●

Approvals of new cell and gene therapies
 

●

Additional approvals of commercial CGT in new geographies
 

●

Additional approvals of CGT in new indications
 

●

Migration of commercial therapies to first or second-line treatment
 

●

An eventual transition to allogeneic therapies

 

We remain confident that we will achieve our Q4 2024 run rate aspirational financial goals of $250 million in revenue, 50 points of adjusted gross margin and 30 points of adjusted EBITDA.”

 

BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business.

 

Total revenue for 2023 is expected to range from $188 million to $202 million, reflecting year-over-year growth of 16% to 25%. Excluding COVID-19-related revenue, this range reflects year-over-year growth of 26% to 35%. Approximately 45% of 2023 total revenue is expected in the first half of the year and approximately 55% in the second half of the year, reflecting typical seasonality. Revenue guidance for 2023 does not include any COVID-19-related revenue.

 

Expectations for 2023 total revenue include the following platform contributions:

 

 

●

Cell processing platform: $89.0 million to $93.0 million, an increase of 30% to 35% over 2022.

 

 

●

Freezers and Thaw Systems platform: $72.5 million to $79.0 million, an increase of 9% to 18% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 13% to 23%.

 

 

●

Storage and Storage Services platform: $26.5 million to $30.0 million, flat to an increase of 13% over 2022. Excluding COVID-19-related revenue, year-over-year growth of 64% to 86%.

 

Management expects gross margin and adjusted EBITDA expansion in 2023.

 

Conference Call & Webcast

 

Management will discuss the Company's financial results, provide a general business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT).

 

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. The conference ID number is 3739539. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com/ for 90 days.

 

5 of 13
 

 

pic1.jpg

 

About BioLife Solutions

 

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system,  high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools. For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

 

Cautions Regarding Forward Looking Statements

 

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the Company, the Company's ability to implement its business strategy and anticipated business and operations, the expected synergies between the Company and the companies and products that it has acquired, the potential utility of and market for the Company's products and services, including the adoption of the Company’s products for new clinical candidates in connection with expected clinical trials, and the Company’s ability to cross sell its products and services, guidance for financial results for 2023, 2024 and 2025, including regarding potential revenue growth and changes in product mix of total revenue and gross margin, the Company's anticipated future growth strategy, including the acquisition of synergistic cell and gene therapy manufacturing tools and services or technologies, regulatory approvals and/or commercial manufacturing of our customers' products, and potential customer revenue. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, unexpected costs, charges or expenses resulting from our acquisitions, market adoption of the Company’s products, the ability of the Company to continue to implement its business strategy, uncertainty regarding third-party market projections, market volatility, competition, litigation, the impact of the COVID-19 pandemic and supply chain issues, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

 

Non-GAAP Measures of Financial Performance:

 

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: adjusted gross profit and gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. When analyzing the Company's operating results, investors should not consider non-GAAP measures as substitutes for the comparable financial measures prepared in accordance with GAAP.

 

6 of 13
 

 

pic1.jpg

 

 

Media & Investor Relations

 

At the Company

 

Troy Wichterman

Chief Financial Officer

(425) 402-1400

twichterman@biolifesolutions.com

 

 

Investors

 

LHA Investor Relations

Jody Cain

(310) 691-7100

jcain@lhai.com

 

7 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share amounts)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands, except per share and share data)

  

2022

    

2021

    

2022

    

2021

  
                                 

Product revenue

   $ 37,796     $ 31,468     $ 136,000     $ 101,913  

Service revenue

     4,168       3,400       15,308       9,817  

Rental revenue

     2,295       2,436       10,451       7,426  

Total revenue

     44,259       37,304       161,759       119,156  

Costs and operating expenses:

                                

Cost of product, rental, and service revenue (exclusive of Intangible asset amortization)

     30,287       31,140       107,937       82,108  

Research and development

     4,164       3,571       14,798       11,821  

Sales and marketing

     5,987       4,778       21,570       14,006  

General and administrative

     12,575       10,713       47,670       33,668  

Intangible asset amortization

     1,457       2,863       9,696       8,202  

Acquisition costs

     -       20       18       1,636  

Change in fair value of contingent consideration

     (1,405 )     1,790       (4,754 )     2,875  

Intangible asset impairment charges

     40,464       -       110,364       -  

Total operating expenses

     93,529       54,875       307,299       154,316  

Operating loss

     (49,270 )     (17,571 )     (145,540 )     (35,160 )
                                 

Other income (expense), net

                                

Change in fair value of warrant liability

     -       -       -       (121 )

Change in fair value of investments

     -       -       697       -  

Interest expense, net

     (438 )     (118 )     (687 )     (485 )

Other expense

     432       299       703       289  

Gain on acquisition of Sexton Biotechnologies, Inc.

     -       -       -       6,451  

Total other (expense) income

     (6 )     181       713       6,134  
                                 

Loss before income tax benefit

     (49,276 )     (17,390 )     (144,827 )     (29,026 )

Income tax benefit

     86       2,578       5,022       20,118  

Net loss

   $ (49,190 )   $ (14,812 )   $ (139,805 )   $ (8,908 )
                                 

Net loss attributable to common shareholders

                                

Basic and Diluted

   $ (1.15 )   $ (0.36 )   $ (3.29 )   $ (0.23 )

Diluted

   $ (1.15 )   $ (0.36 )   $ (3.29 )   $ (0.23 )

Weighted average shares used to compute loss per share attributable to common shareholders:

                                

Basic

     42,791,040       41,675,256       42,481,027       38,503,944  

Diluted

     42,791,040       41,675,256       42,481,027       38,503,944  

 

8 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share amounts)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  
                                 

NET LOSS

   $ (49,190 )   $ (14,812 )   $ (139,805 )   $ (8,908 )

Other comprehensive income/(loss)

     579       (119 )     (397 )     (282 )

COMPREHENSIVE LOSS

   $ (48,611 )   $ (14,931 )   $ (140,202 )   $ (9,190 )

 

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited, amounts in thousands)

 

 

   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

  

Cash, cash equivalents, and marketable securities

   $ 64,065     $ 69,870  

Working capital

     93,870       83,388  

Current assets

     138,452       126,088  

Current liabilities

     44,582       42,700  

Total assets

     450,229       554,285  
                 

Long-term obligations

     41,459       33,539  

Accumulated deficit

     (246,915 )     (107,109 )

Total shareholders' equity

   $ 364,188     $ 478,046  

 

9 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION

(Unaudited, amounts in thousands)

 

 

   

Year Ended

  
   

December 31,

  

(In thousands)

  

2022

    

2021

  

Net cash used in operating activities

   $ (8,489 )   $ (4,593 )

Net cash used in investing activities

     (58,117 )     (13,192 )

Net cash provided by (used in) financing activities

     16,317       (2,778 )

Effects of currency translation

     (108 )     (23 )

Net decrease in cash, cash equivalents and restricted stock

   $ (50,397 )   $ (20,586 )

 

10 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP (ADJUSTED) GROSS PROFIT

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP GROSS PROFIT

   $ 13,329     $ 4,675     $ 48,815     $ 32,491  

GAAP GROSS MARGIN

     30

%

     13

%

     30

%

     27

%
                                 

ADJUSTMENTS TO GROSS PROFIT:

                                

Inventory step-up

     -       -       251       1,130  

Intangible asset amortization

     733       1,489       5,007       4,557  

ADJUSTED GROSS PROFIT

   $ 13,972     $ 6,164     $ 54,073     $ 38,178  

ADJUSTED GROSS MARGIN

     32

%

     17

%

     33

%

     32

%

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING EXPENSES TO NON-GAAP (ADJUSTED) OPERATING EXPENSES

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP OPERATING EXPENSES

   $ 93,529     $ 54,875     $ 307,299     $ 154,316  
                                 

ADJUSTMENTS TO OPERATING EXPENSES:

                                

Cost of product, rental, and service revenue

     (30,287 )     (31,140 )     (107,937 )     (82,108 )

Acquisition costs

     -       (20 )     (18 )     (1,636 )

Intangible asset amortization

     (1,457 )     (2,863 )     (9,696 )     (8,202 )

Loss on disposal of assets

     (595 )     170       (683 )     145  

Change in fair value of contingent consideration

     1,405       (1,790 )     4,754       (2,875 )

Intangible asset impairment charges

     (40,464 )     -       (110,364 )     -  

ADJUSTED OPERATING EXPENSES

   $ 22,131     $ 19,232     $ 83,355     $ 59,640  

 

11 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP OPERATING INCOME (LOSS) TO NON-GAAP (ADJUSTED) OPERATING INCOME (LOSS)

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP OPERATING LOSS

   $ (49,270 )   $ (17,571 )   $ (145,540 )   $ (35,160 )
                                 

ADJUSTMENTS TO OPERATING LOSS:

                                

Inventory step-up

     -       -       251       1,130  

Acquisition costs

     -       20       18       1,636  

Intangible asset amortization

     1,457       2,863       9,696       8,202  

Loss on disposal of assets

     595       (170 )     683       (145 )

Change in fair value of contingent consideration

     (1,405 )     1,790       (4,754 )     2,875  

Intangible asset impairment charges

     40,464       -       110,364       -  

ADJUSTED OPERATING LOSS

   $ (8,159 )   $ (13,068 )   $ (29,282 )   $ (21,462 )

 

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) NET INCOME (LOSS)

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP NET LOSS

   $ (49,190 )   $ (14,812 )   $ (139,805 )   $ (8,908 )
                                 

ADJUSTMENTS TO NET LOSS:

                                

Inventory step-up

     -       -       251       1,130  

Acquisition costs

     -       20       18       1,636  

Intangible asset amortization

     1,457       2,863       9,696       8,202  

Loss on disposal of assets

     595       (170 )     683       (145 )

Change in fair value of contingent consideration

     (1,405 )     1,790       (4,754 )     2,875  

Change in fair value of investments

     -       -       (697 )     -  

Change in fair value of warrant liability

     -       -       -       (121 )

Income tax benefit

     (86 )     (2,578 )     (5,022 )     (20,118 )

Intangible asset impairment charges

     40,464       -       110,364       -  

ADJUSTED NET LOSS

   $ (8,165 )   $ (12,887 )   $ (29,266 )   $ (15,449 )

 

12 of 13
 

 

pic1.jpg

 

BIOLIFE SOLUTIONS, INC.

RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP (ADJUSTED) EBITDA

(Unaudited, amounts in thousands)

 

 

   

Three Months Ended

    

Year Ended

  
   

December 31,

    

December 31,

  

(In thousands)

  

2022

    

2021

    

2022

    

2021

  

GAAP NET INCOME/(LOSS)

   $ (49,190 )   $ (14,812 )   $ (139,805 )   $ (8,908 )
                                 

ADJUSTMENTS:

                                

Interest expense/(income), net

     438       118       687       485  

Income tax benefit

     (86 )     (2,578 )     (5,022 )     (20,118 )

Depreciation

     1,790       1,790       6,834       4,801  

Intangible asset amortization

     1,457       2,863       9,696       8,202  

EBITDA

   $ (45,591 )   $ (12,619 )   $ (127,610 )   $ (15,538 )
                                 

OTHER ADJUSTMENTS:

                                

Share-based compensation (non-cash)

     7,663       5,082       25,334       13,973  

Inventory step-up

     -       -       251       1,130  

Acquisition costs

     -       20       18       1,636  

Loss on disposal of assets

     595       (170 )     683       (145 )

Change in fair value of contingent consideration

     (1,405 )     1,790       (4,754 )     2,875  

Change in fair value of investments

     -       -       (697 )     -  

Change in fair value of warrant liability

     -       -       -       121  

Intangible asset impairment charges

     40,464       -       110,364       -  

ADJUSTED EBITDA

   $ 1,726     $ (5,897 )   $ 3,589     $ 4,052  

 

 

# # #

 

13 of 13

 EX-101.SCH 3 blfs-20230316.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 blfs-20230316_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 blfs-20230316_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 blfs-20230316_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 pic1.jpg begin 644 pic1.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Mar. 16, 2023
Document Information [Line Items]  
Entity, Registrant Name BIOLIFE SOLUTIONS, INC.
Document, Type 8-K
Document, Period End Date Mar. 16, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36362
Entity, Tax Identification Number 94-3076866
Entity, Address, Address Line One 3303 Monte Villa Parkway
Entity, Address, City or Town Bothell
Entity, Address, State or Province WA
Entity, Address, Postal Zip Code 98021
City Area Code 425
Local Phone Number 402-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security BioLife Solutions, Inc. Common Stock
Trading Symbol BLFS
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000834365
XML 9 bioli20230316_8k_htm.xml IDEA: XBRL DOCUMENT 0000834365 2023-03-16 2023-03-16 false 0000834365 8-K 2023-03-16 BIOLIFE SOLUTIONS, INC. DE 001-36362 94-3076866 3303 Monte Villa Parkway Bothell WA 98021 425 402-1400 false false false false BioLife Solutions, Inc. Common Stock BLFS NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.blfs.com/20230316/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports bioli20230316_8k.htm blfs-20230316.xsd blfs-20230316_def.xml blfs-20230316_lab.xml blfs-20230316_pre.xml ex_489845.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bioli20230316_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "blfs-20230316_def.xml" ] }, "inline": { "local": [ "bioli20230316_8k.htm" ] }, "labelLink": { "local": [ "blfs-20230316_lab.xml" ] }, "presentationLink": { "local": [ "blfs-20230316_pre.xml" ] }, "schema": { "local": [ "blfs-20230316.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "blfs", "nsuri": "http://www.blfs.com/20230316", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20230316_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.blfs.com/20230316/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "bioli20230316_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.blfs.com/20230316/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001437749-23-006923-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-006923-xbrl.zip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end